Ikena Oncology, Inc. (IKNA) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
IKNA currently has 11.2M outstanding shares. with significant dilution risk as 22.8M authorized shares could dilute existing holders by 202.9%. The company has minimally diluted shareholders by 0.26% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 11.2M shares outstanding |
11M | 23M |
| Apr 02, 2026 |
POS AM filing: This prospectus relates to the resale by certain of the selling stockholders named in this prospectus of 2,508,337 shares of common stock, par value $0.001 per share, issued in a private placement on July 25, 2025. |
11M | 23M |
| Nov 12, 2025 |
10-Q filing | 11.2M shares outstanding |
11M | 25M |
| Sep 08, 2025 |
S-1 filing: This prospectus relates to the resale by certain of the selling stockholders named in this prospectus of 2,508,337 shares of common stock, par value $0.001 per share, issued in a private placement on July 25, 2025. |
48M | 25M |
| May 08, 2025 |
10-Q filing | 48.3M shares outstanding |
48M | 23M |
| Mar 06, 2025 |
10-K filing | 48.3M shares outstanding |
48M | 23M |
| Nov 07, 2024 |
10-Q filing | 48.3M shares outstanding |
48M | 23M |
| Aug 08, 2024 |
10-Q filing | 48.3M shares outstanding |
48M | 23M |
| May 13, 2024 |
10-Q filing | 48.3M shares outstanding |
48M | 23M |
| Mar 12, 2024 |
10-K filing | 48.3M shares outstanding |
48M | 23M |
| Nov 09, 2023 |
10-Q filing | 43.4M shares outstanding |
43M | 23M |
| Aug 18, 2023 |
S-3 filing: This S-3 filing relates to the proposed resale or other disposition of 5,954,091 shares of common stock by selling stockholders. |
39M | 23M |
| Aug 10, 2023 |
10-Q filing | 39.3M shares outstanding |
39M | 17M |
| May 15, 2023 |
10-Q filing | 36.3M shares outstanding |
36M | 17M |
| Mar 14, 2023 |
10-K filing | 36.2M shares outstanding |
36M | 17M |
| Nov 07, 2022 |
10-Q filing | 36.3M shares outstanding |
36M | 17M |
| Aug 11, 2022 |
10-Q filing | 36.2M shares outstanding |
36M | 17M |
| May 12, 2022 |
10-Q filing | 36.2M shares outstanding |
36M | 17M |
| Apr 27, 2022 |
S-3 filing: Ikena Oncology, Inc. is offering common stock, preferred stock, and debt securities for an aggregate amount of $300,000,000 and common stock through an at-the-market offering for up to $100,000,000. |
36M | 17M |
| Mar 17, 2022 |
10-K filing | 36.1M shares outstanding |
36M | 17M |
| Nov 10, 2021 |
10-Q filing | 35.9M shares outstanding |
36M | 17M |
| Aug 12, 2021 |
10-Q filing | 35.9M shares outstanding |
36M | 17M |
| May 13, 2021 |
10-Q filing | 35.9M shares outstanding |
36M | 17M |
| Mar 22, 2021 |
S-1/A filing: S-1/A filing for an offering of common stock with underwriters having the option to purchase additional shares. The company intends to use the net proceeds from this offering to advance the development of its targeted oncology programs and to fund working capital and general corporate purposes. |
30M | 17M |
| Mar 05, 2021 |
S-1 filing: This S-1 filing describes a company offering common stock, with underwriters having an option to purchase additional shares. The company intends to use the net proceeds from this offering to advance the development of their targeted oncology programs, and for working capital and general corporate purposes. |
190M | 0 |